3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
29
Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Stomach Neoplasms
10
Lymphatic Metastasis
7
Head and Neck Neoplasms
7
Melanoma
6
Esophageal Neoplasms
6
Carcinoma, Hepatocellular
6
Uterine Cervical Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Ovarian Neoplasms
4
Sarcoma
3
Prostatic Neoplasms
3
Lymphedema
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Vulvar Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solitary Pulmonary Nodule
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Peritoneal Neoplasms
2
Osteosarcoma
2
Multiple Pulmonary Nodules
2
Margins of Excision
2
Giant Cell Tumor of Bone
2
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
napabucasin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thoracic Neoplasms
×
Indocyanine Green
×
Clear all
NCT02111824
2021-09-17
MIMIG
The Methodist Hospital Research Institute
Phase 1
Terminated
7 enrolled